Tumour‐associated macrophages as a novel target of VEGI‐251 in cancer therapy

作者：Xinhuai Dong, Xuan Huang, Zhicheng Yao, Yun Wu, Delin Chen, Chahui Tan, Jiajie Lin, Danrui Zhang, Yiwen Hu, Jueheng Wu, Guohong Wei, Xun Zhu · 发表于：Journal of Cellular and Molecular Medicine · 年份：2020 · DOI：10.1111/jcmm.15421 · 被引用次数：7 · 研究领域：Immune cells in cancer、Phagocytosis and Immune Regulation、Histone Deacetylase Inhibitors Research

Tumour-associated macrophages (TAMs), which possess M2-like characters and are derived from immature monocytes in the circulatory system, represent a predominant population of inflammatory cells in solid tumours. TAM infiltration in tumour microenvironment can be used as an important prognostic marker in many cancer types and is a potential target for cancer prevention or treatment. VEGI-251 not only is involved in the inhibition of tumour angiogenesis, but also participates in the regulation of host immunity. This work aimed to investigate the involvement of VEGI-251 in the regulation of specific antitumour immunity. We found that recombinant human VEGI-251(rhVEGI-251) efficiently mediated the elimination of TAMs in tumour tissue in mice, and induced apoptosis of purified TAMs in vitro. During this process, caspase-8 and caspase-3 were activated, leading to PARP cleavage and apoptosis. Most importantly, we further elucidated the mechanism underlying VEGI-251-triggered TAM apoptosis, which suggests that ASK1, an intermediate component of the VEGI-251, activates the JNK pathway via TRAF2 in a potentially DR3-dependent manner in the process of TAM apoptosis. Collectively, our findings provide new insights into the basic mechanisms underlying the actions of VEGI-251 that might lead to future development of antitumour therapeutic strategies using VEGI-251 to target TAMs.